Cytek Biosciences reports preliminary Q4 revenue of $62 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Grand Canyon Education places CFO on leave amid stock trade probe
- Funds sell $44bn in semiconductors on AI concerns
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
January 12, 2026 5:00 AM ESTFREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025.
Cytek expects its total revenue for the full year 2025 to be approximately $201 million. Expected revenue for the fourth quarter of 2025 of approximately $62 million represents growth of 8% compared to the fourth quarter of 2024 and 19% compared to the third quarter of 2025.
Our fourth quarter revenue growth over the prior year represents a meaningful acceleration of growth compared to the prior quarters in... More
